Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 214,304
  • Shares Outstanding, K 45,988
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.63
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +16.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +69.45%
on 11/12/19
11.38 -59.05%
on 11/07/19
-6.00 (-56.29%)
since 11/06/19
3-Month
2.75 +69.45%
on 11/12/19
13.58 -65.68%
on 10/23/19
-5.36 (-53.49%)
since 09/06/19
52-Week
2.75 +69.45%
on 11/12/19
32.85 -85.81%
on 01/14/19
-24.02 (-83.75%)
since 12/06/18

Most Recent Stories

More News
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

GILD : 67.08 (+1.74%)
BIIB : 300.26 (+0.29%)
XLRN : 49.88 (+2.47%)
CELG : 108.24 (+0.10%)
AMRN : 22.45 (+2.93%)
SLDB : 4.66 (+7.62%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB

Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB). Such investors are advised to contact Robert S. Willoughby...

SLDB : 4.66 (+7.62%)
Solid Biosciences Provides SGT-001 Program Update

Solid Biosciences Inc. (Nasdaq: SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the company that IGNITE DMD, its Phase I/II...

SLDB : 4.66 (+7.62%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

SLDB : 4.66 (+7.62%)
Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic...

SLDB : 4.66 (+7.62%)
Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders(1) that summarizes the evidence supporting the function of microdystrophin-associated...

SLDB : 4.66 (+7.62%)
Will Solid Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Solid Biosciences.

SLDB : 4.66 (+7.62%)
Sarepta Stock Falls as FDA Denies Approval to Golodirsen

The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

PFE : 38.29 (+0.68%)
SRPT : 109.46 (-0.45%)
BOLD : 59.25 (+0.07%)
SLDB : 4.66 (+7.62%)
Solid Biosciences Surges on DMD Gene Therapy Study Amendments

Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.

PFE : 38.29 (+0.68%)
SRPT : 109.46 (-0.45%)
SLDB : 4.66 (+7.62%)
BOLD : 59.25 (+0.07%)
Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update

- Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial -

SLDB : 4.66 (+7.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade SLDB with:

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 4.99
1st Resistance Point 4.82
Last Price 4.66
1st Support Level 4.41
2nd Support Level 4.17

See More

52-Week High 32.85
Fibonacci 61.8% 21.35
Fibonacci 50% 17.80
Fibonacci 38.2% 14.25
Last Price 4.66
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar